Development of a blOOdtest for uteRine Sarcoma – Monitoring (DOORS-M)
Research type
Research Study
Full title
Development of a blOOdtest for uteRine Sarcoma – Monitoring
IRAS ID
350807
Contact name
Esther Moss
Contact email
Sponsor organisation
University of Leicester
Duration of Study in the UK
2 years, 11 months, 30 days
Research summary
Uterine sarcomas account for 3 in 100 of cancers arising from the uterus, or womb. They can be difficult to diagnose since they have many of the same symptoms and scan features as uterine fibroids. At present there is no blood test that can detect uterine sarcoma recurrence, and guide patient management. Circulating tumour DNA (ctDNA) is fragments of cancer released from cancer cells that can be
detected within the blood and can be useremoved at surgery. We will investigate whether artificial intelligence analysis of the
images can better differentiate sarcomas from fibroids. We also aim to develop a blood test to differentiate betweend to diagnose and monitor cancers. The genetic profile of uterine sarcomas is complex, and designing a ctDNA-based blood test to detect uterine sarcomas needs to take these complexities into
account, and to ensure that there is a clear difference from the profile of fibroids.
This project aims to pilot the use of a ctDNA-based test to help diagnose and monitor patients with uterine sarcomas. We will recruit patients who have previously been diagnosed with a uterine sarcoma for blood tests and analysis their
scan images and sarcoma/biopsies.REC name
South Central - Berkshire B Research Ethics Committee
REC reference
25/SC/0108
Date of REC Opinion
13 May 2025
REC opinion
Further Information Favourable Opinion